Skip to main content
. 2021 Mar 17;12(4):282. doi: 10.1038/s41419-021-03556-4

Fig. 6. LSD1 inhibitor enhances the efficacy of anti-CD47/PD-L1 immunotherapy therapy in cervical cancer allograft model in vivo.

Fig. 6

A A combination of LSD1 inhibitors (50 mg/kg, three times a week) and anti-CD47 mAb (100 µg per mouse, three times a week) showed more significant inhibition of tumor growth than single drug administration (n = 4 per group). Evaluation of the appearance (B) and weights (C) of tumors in the four groups demonstrated the enhanced efficacy of anti-CD47 immunotherapy therapy when combined with an LSD1 inhibitor in vivo. D–F Enhanced treatment efficacy was also achieved with a combined administration of LSD1 inhibitors (50 mg/kg, three times a week) and anti-PD-L1 mAb (300 µg per mouse, three times a week) (n = 4 per group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.